These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32552241)

  • 1. Small molecule glucagon receptor antagonists: an updated patent review (2015-2019).
    Cheng C; Jabri S; Taoka BM; Sinz CJ
    Expert Opin Ther Pat; 2020 Jul; 30(7):509-526. PubMed ID: 32552241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).
    Filipski KJ
    Expert Opin Ther Pat; 2015 Jul; 25(7):819-30. PubMed ID: 25828189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010).
    Shen DM; Lin S; Parmee ER
    Expert Opin Ther Pat; 2011 Aug; 21(8):1211-40. PubMed ID: 21635155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing loss of glycemic control in middle-aged patients with diabetes: the role of GLP-1 receptor agonists in combination-therapy regimens.
    Repas TB
    J Am Osteopath Assoc; 2014 May; 114(5 Suppl 2):S14-21. PubMed ID: 24769504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
    Kazda CM; Ding Y; Kelly RP; Garhyan P; Shi C; Lim CN; Fu H; Watson DE; Lewin AJ; Landschulz WH; Deeg MA; Moller DE; Hardy TA
    Diabetes Care; 2016 Jul; 39(7):1241-9. PubMed ID: 26681715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
    Scheen AJ; Paquot N; Lefèbvre PJ
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1373-1389. PubMed ID: 29052441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon as a target for the treatment of Type 2 diabetes.
    Sloop KW; Michael MD; Moyers JS
    Expert Opin Ther Targets; 2005 Jun; 9(3):593-600. PubMed ID: 15948676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon receptor antagonism induces increased cholesterol absorption.
    Guan HP; Yang X; Lu K; Wang SP; Castro-Perez JM; Previs S; Wright M; Shah V; Herath K; Xie D; Szeto D; Forrest G; Xiao JC; Palyha O; Sun LP; Andryuk PJ; Engel SS; Xiong Y; Lin S; Kelley DE; Erion MD; Davis HR; Wang L
    J Lipid Res; 2015 Nov; 56(11):2183-95. PubMed ID: 26373568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
    Kelly RP; Garhyan P; Raddad E; Fu H; Lim CN; Prince MJ; Pinaire JA; Loh MT; Deeg MA
    Diabetes Obes Metab; 2015 Apr; 17(4):414-22. PubMed ID: 25656305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
    Tzefos M; Olin JL
    Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
    Bagger JI; Knop FK; Holst JJ; Vilsbøll T
    Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing diabetes in patients with diabetes of long duration.
    Triplitt CL
    Diabetes Educ; 2012; 38(4 Suppl):23S-30S; quiz 31S. PubMed ID: 22661393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
    Pandey J; Tamrakar AK
    Expert Opin Ther Pat; 2019 May; 29(5):369-384. PubMed ID: 31026402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in non-peptide glucagon receptor antagonists.
    Madsen P; Brand CL; Holst JJ; Knudsen B
    Curr Pharm Des; 1999 Sep; 5(9):683-691. PubMed ID: 10495358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
    Kazda CM; Frias J; Foga I; Cui X; Guzman CB; Garhyan P; Heilmann C; Yang JA; Hardy TA
    Diabetes Obes Metab; 2017 Aug; 19(8):1071-1077. PubMed ID: 28191913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
    Kazierad DJ; Bergman A; Tan B; Erion DM; Somayaji V; Lee DS; Rolph T
    Diabetes Obes Metab; 2016 Aug; 18(8):795-802. PubMed ID: 27059951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Van Gaal LF; Gutkin SW; Nauck MA
    Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
    Tan X; Cao X; Zhou M; Zou P; Hu J
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.